Promising early trial results show engineered immune cells may help buffer against cancer relapse after bone marrow transplantation
April 21, 2016
| By Sabrina Richards / Fred Hutch News Service
Dr. Phil Greenberg’s team at Fred Hutch has developed methods to genetically modify T cells, a type of immune cell, to specifically seek out cancer cells while they ignore healthy cells. On Wednesday, he presented results of an early-stage trial at the American Association for Cancer Research annual conference in New Orleans that appear to show promise in preventing disease relapse after blood stem cell transplantation.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.